Shanghai Henlius Biotech Inc
HKEX:2696
Shanghai Henlius Biotech Inc
Long-Term Debt
Shanghai Henlius Biotech Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
Shanghai Henlius Biotech Inc
HKEX:2696
|
Long-Term Debt
ÂĄ1.3B
|
CAGR 3-Years
26%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Long-Term Debt
ÂĄ1.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
||
Innovent Biologics Inc
HKEX:1801
|
Long-Term Debt
ÂĄ2.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Long-Term Debt
ÂĄ127.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Long-Term Debt
ÂĄ398.2m
|
CAGR 3-Years
65%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Imeik Technology Development Co Ltd
SZSE:300896
|
Long-Term Debt
ÂĄ37.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Shanghai Henlius Biotech Inc
Glance View
In the heart of China's bustling financial district, Shanghai Henlius Biotech Inc. stands proud as a beacon of innovation in the biopharmaceutical industry. Founded in 2010, Henlius has rapidly grown to become a notable player in the development of monoclonal antibodies, with a focus on oncology, autoimmune disorders, and ophthalmic conditions. The company's business model is rooted in its robust research and development capabilities, which are supported by strategic partnerships and a dedicated pipeline. By harnessing state-of-the-art technology and a global talent pool, Henlius crafts biosimilar and innovative biological drugs designed to meet the escalating health needs across the globe. With a strong focus on cutting-edge R&D, they have successfully commercialized several key products that have gained regulatory approval, allowing them to penetrate both domestic and international markets. Revenue flows into Henlius through a diversified portfolio that stretches beyond drug development to encompass manufacturing and sales partnerships. By leveraging their fully-integrated biopharmaceutical platform, Henlius not only develops its proprietary medications but also collaborates with other pharmaceutical giants to bring products to market efficiently. These collaborations often translate into licensing agreements and royalties, which provide Henlius with recurring income streams. The company's ability to navigate complex regulatory environments and its strategic expansion into global markets – including Europe, Southeast Asia, and Latin America – further reinforces its revenue-generating capacity. Thus, Henlius stands as a testament to the power of strategic ingenuity and cutting-edge science in the ever-evolving landscape of global healthcare.
See Also
What is Shanghai Henlius Biotech Inc's Long-Term Debt?
Long-Term Debt
1.3B
CNY
Based on the financial report for Dec 31, 2023, Shanghai Henlius Biotech Inc's Long-Term Debt amounts to 1.3B CNY.
What is Shanghai Henlius Biotech Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
27%
Over the last year, the Long-Term Debt growth was 12%. The average annual Long-Term Debt growth rates for Shanghai Henlius Biotech Inc have been 26% over the past three years , 27% over the past five years .